REMOXIPRIDE, A SPECIFIC D2-DOPAMINE ANTAGONIST - AN EXAMINATION OF ITS SELF-ADMINISTRATION LIABILITY AND ITS EFFECTS ON D-AMPHETAMINE SELF-ADMINISTRATION

The self-administration liability of remoxipride, a specific dopamine D2 antagonist, by laboratory rats was evaluated using an intravenous self-administration paradigm. It was observed that remoxipride failed to support self-administration behavior across the three doses tested. In addition, remoxipride pretreatment attenuated d-amphetamine self-administration. The findings of the present study provide support for the notion that remoxipride appears to have functional similarity in self-administration paradigms as other D2 antagonists.